Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin

Morio Nakamura, Naoki Hasegawa, Naoki Miyao, Takahiro Nakajima, Takeshi Terashima, Fumio Sakamaki, Rika Hiraoka, Hiroaki Matsubara, Yoshitaka Oyamada, Makoto Yonemaru, Kazumi Nishio, Naoto Shimada, Ichiro Kawada, Katsuhiko Naoki, Sadatomo Tasaka, Tomoyasu Nishimura, Akitoshi Ishizaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

[Objective]: This study was conducted in patients of secondary infection with chronic respiratory disease in order to compare 5 day short-course therapies employing gatifloxacin(GFLX) and levofloxacin(LVFX). In addition to the shortening of treatment periods, we also investigated the economic efficiency of this medical treatment. [Materials and methods]: A total of 74 patients with secondary infection in chronic respiratory disease were enrolled and treated with the study drugs. The study was conducted between September, 2006 and April, 2007 at Keio University Hospital and its affiliated hospitals and clinics. This was a randomized study in which patients were randomly assigned to one of the following two treatment groups: GFLX group (200 mg twice daily for patients aged ≧ 65 years and 400 mg twice daily in patients aged < 65 years), LVFX group (400 mg twice daily). The duration of antibiotic therapy was 5 days. [Results]: 61 patients (GFLX group: 32, LVFX group: 29) were evaluated for the efficacy of the medications, 74 patients (GFLX group: 37, LVFX group: 37) were evaluated for side effects, and 63 patients (GFLX group: 30, LVFX group: 33) were evaluated for abnormal laboratory results from a total of 74 patients. Clinical efficacy was 90.6% (29/32) in the GFLX group and 89.7% (26/29) in the LVFX group. Side effects were observed in 2 cases in the GFLX group, and 2 abnormal laboratory results were observed (1 in the GFLX group and 1 in the LVFX group). These cases were all mild in nature. [Conclusion]: Conventional management recommends 7-14 days of antibiotic therapy for secondary infection in patients with chronic respiratory disease. However, the optimum duration of treatment is less clear. This study suggests that for secondary infection in chronic respiratory disease, 5 day short-course therapy employing antibiotics therapy can be clinically successful. In terms of the economic efficiency of this medical treatment, GFLX is superior to LVFX due to the lower cost of this drug. These results show that therapy involving a 5 day short-course using GFLX is of greater benefit than therapy involving the use of LVFX.

Original languageEnglish
Pages (from-to)451-462
Number of pages12
JournalJapanese Journal of Chemotherapy
Volume55
Issue number6
Publication statusPublished - 2007 Nov 1

    Fingerprint

Keywords

  • 5-day therapy
  • Chronic respiratory disease
  • Gatifloxacin
  • Levofloxacin
  • Secondary infection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Nakamura, M., Hasegawa, N., Miyao, N., Nakajima, T., Terashima, T., Sakamaki, F., Hiraoka, R., Matsubara, H., Oyamada, Y., Yonemaru, M., Nishio, K., Shimada, N., Kawada, I., Naoki, K., Tasaka, S., Nishimura, T., & Ishizaka, A. (2007). Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin. Japanese Journal of Chemotherapy, 55(6), 451-462.